InSightec is inviting ASTRO 2014 attendees to learn about its Oncology MR-guided Focused Ultrasound solution for alleviating pain caused by bone mets

ASTRO 2014: The American Society for Radiation Oncology 56th Annual Meeting - The Moscone Center, San Francisco, USA, September 14-17

News provided by

InSightec

Sep 12, 2014, 08:00 ET

HAIFA, Israel, Sept. 12, 2014 /PRNewswire/ -- InSightec, a world leader in MR-guided Focused Ultrasound (MRgFUS) will be on site at the ASTRO 56^th annual meeting to present its MR-guided Focused Ultrasound solution for alleviating pain caused by bone mets.

ASTRO's annual meeting is the premier radiation oncology scientific event in the world, attracting more than 11,000 attendees each year. The 2014 meeting will look specifically at how scientific innovations combine technology and biology to advance cancer treatments, as well as improve patient outcomes and quality of life.

InSightec believes that MRgFUS is a technology that is revolutionizing medicine as we know it. Therefore, it will present at the event its highly innovative MR-guided Focused Ultrasound solution for alleviating pain caused by painful bone metastases.

This treatment option offers several strong advantages that make more and more patients as well as Radiation Oncologists consider it as a new, solid and effective alternative solution for treating pain caused by bone metastases. One of the most appealing advantages being that it requires no stoppage of planned or ongoing chemotherapy and therefore provides leverage for patient management.

It also allows for real-time feedback, so there are no surprises at the end of the procedure and patients enjoy immediate pain alleviation. Clinical evidence shows high success rates as well as a high safety profile. All these clear advantages drove leading physicians in prominent medical facilities around the world to adopt InSightec's Oncology offering.

Today, researchers around the world are utilizing InSightec's technology to treat liver cancer, pancreatic cancer, prostate cancer, and breast cancer.

InSightec's technology is currently FDA approved to treat bone metastases, and uterine fibroids. Treatment of additional indications is expected in the near future.

We invite you to visit InSightec at the GE booth # 2228 to learn more about our unique non-invasive technology for treating cancer.

Note to editors

ABOUT INSIGHTEC

INSIGHTEC is a world leader in MR-guided Focused Ultrasound (MRgFUS). The company, founded in 1999, has developed a completely non-invasive therapy platform that transforms medicine in an expanding number of neurosurgery, oncology and gynecology indications. MRgFUS is already adopted and used by world recognized physicians in more than 120 leading medical facilities around the world, who see the tremendous clinical and economical value of the InSightec therapy platform.

The company has received numerous awards for innovation from well-respected organizations including the Wall Street Journal, the European Union and TIME Magazine. The company is privately held by GE Healthcare, Elbit Imaging, York Capital Management and MediTech Advisors. For more information please visit: www.insightec.com

Media Contact

Xen Mendelsohn Aderka
VP of Marketing
InSightec
[email protected]
+972-4-8131309

SOURCE InSightec